Plexiform Neurofibroma
NF1-associated Plexiform Neurofibromas

NF1-associated Plexiform Neurofibromas

This study will evaluate the confirmed complete and partial response rate of the study
drug using volumetric MRI analysis in participants with an inoperable NF1-associated
PN that is causing significant morbidity.

Key Eligibility Criteria

  • ≥2 years of age
  • Either a clinical diagnosis of NF1 using the National Institute of Health (NIH)
  • Consensus Conference criteria, OR a constitutional NF1 mutation documented
  • in a certified lab
  • Target PN that is causing significant morbidity
  • Target PN that is deemed inoperable
  • Target PN that is amenable to MRI analysis (for those aged ≥18, PN must also be
  • amenable to percutaneous biopsy)
  • Has never received therapy with PD-0325901 or any other MEK1/2 inhibitor

For more information

For more information about the ReNeu study, please contact

  • Hans Shuhaiber, MD, Director of NF clinic and PI ( principal investigator)
  • Victoria Hope CRC clinical care coordinator
  • Hans Shuhaiber (352) 294-5000 (352) 273-5550 (24 hours)
  • Victoria Hope (352) 733-2436 or Amanda Cowsert (352) 733- 2435